Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
National Institutes of Health Clinical Center (CC)
European Myeloma Network B.V.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
University of California, San Francisco
Celgene
Essen Biotech
M.D. Anderson Cancer Center
Senti Biosciences
Juno Therapeutics, a Subsidiary of Celgene
Medical College of Wisconsin
M.D. Anderson Cancer Center
Fate Therapeutics
Thomas Jefferson University
Northside Hospital, Inc.
University of Rochester
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
University of Pennsylvania
Indapta Therapeutics, INC.
Cartesian Therapeutics
Janssen Scientific Affairs, LLC
Thomas Jefferson University
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
Cedars-Sinai Medical Center
Cartesian Therapeutics
Allogene Therapeutics
The First Affiliated Hospital with Nanjing Medical University
Jonsson Comprehensive Cancer Center
Gilead Sciences
Fred Hutchinson Cancer Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gilead Sciences
Dartmouth-Hitchcock Medical Center
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Precision BioSciences, Inc.
Fred Hutchinson Cancer Center
Celyad Oncology SA
Celgene
Melbourne Health